Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Growth in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large growth in short interest in June. As of June 30th, there was short interest totaling 23,589 shares, a growth of 158.0% from the June 15th total of 9,143 shares. Based on an average daily volume of 19,757 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.1% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Xenetic Biosciences Stock Down 2.9%

Shares of NASDAQ XBIO traded down $0.09 during mid-day trading on Wednesday, hitting $2.91. 17,329 shares of the company traded hands, compared to its average volume of 20,366. Xenetic Biosciences has a 1 year low of $1.90 and a 1 year high of $13.93. The stock has a market capitalization of $6.67 million, a price-to-earnings ratio of -2.43 and a beta of 2.19. The business has a 50 day moving average of $3.01 and a two-hundred day moving average of $2.75.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The company had revenue of $0.81 million for the quarter.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission. 15.12% of the stock is currently owned by institutional investors and hedge funds.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.